Paloma Giangrande, Chief Technology Officer
Professional Overview
Paloma Giangrande is a distinguished leader in the biotechnology industry, with a strong track record of driving innovation and advancing cutting-edge therapeutic technologies. As the Chief Technology Officer at Eleven Therapeutics, she is responsible for overseeing the company's technology strategy, leading research and development initiatives, and fostering a culture of scientific excellence.
Experience Summary
Current Role
As the Chief Technology Officer at Eleven Therapeutics, Paloma Giangrande is spearheading the company's efforts to develop transformative gene and cell therapies. In this role, she provides strategic direction for the company's technology platforms, aligns research and development priorities with business objectives, and collaborates closely with cross-functional teams to accelerate the translation of innovative ideas into viable clinical solutions.
Paloma also serves as the Editor in Chief of Molecular Therapy Nucleic Acids, a prestigious scientific journal published by the American Society of Gene & Cell Therapy. In this capacity, she has been instrumental in shaping the direction of the publication, curating high-impact research, and fostering a platform for the dissemination of cutting-edge advancements in the field.
Career Progression
Prior to her current roles, Paloma held various leadership positions in the biotechnology industry, including Vice President of Platform and Discovery Sciences, Biology at Wave Life Sciences and Director at Moderna Therapeutics. In these roles, she played a pivotal role in advancing the development of novel nucleic acid-based therapies, leading cross-functional teams, and driving the translation of scientific discoveries into clinical-stage products.
Earlier in her career, Paloma served as an Assistant Professor at the University of Iowa Hospitals and Clinics and a Research Assistant Professor at Duke University Medical Center, where she conducted groundbreaking research in the field of gene therapy and made significant contributions to the scientific community.
Academic Background
Paloma Giangrande holds a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, where she specialized in the development of innovative gene delivery systems and their applications in gene therapy. Her academic achievements include numerous peer-reviewed publications, prestigious awards, and recognition from her peers for her contributions to the field.
Areas of Expertise
- Gene and cell therapy technology development
- Nucleic acid-based therapeutic platforms
- Translational research and clinical development
- Scientific leadership and strategic planning
- Cross-functional team management and collaboration
Professional Impact
Throughout her career, Paloma Giangrande has made significant contributions to the advancement of gene and cell therapy technologies. She has been instrumental in the development of several cutting-edge therapeutic candidates, which have demonstrated promising results in clinical trials and have the potential to transform the lives of patients.
As a scientific leader and mentor, Paloma has inspired and guided the next generation of researchers, fostering a culture of innovation and excellence within the organizations she has been a part of. Her dedication to scientific rigor and her ability to navigate the complex landscape of the biotechnology industry have earned her the respect and admiration of her peers.
Conclusion
Paloma Giangrande's exceptional technical expertise, strategic vision, and commitment to advancing the field of gene and cell therapy have positioned her as a highly sought-after leader in the biotechnology industry. In her current role as Chief Technology Officer at Eleven Therapeutics, she continues to drive transformative innovation, mentor and inspire the next generation of scientific leaders, and make a lasting impact on the lives of patients worldwide.
